Preparation for Regulatory Agency Meetings and Initiation of Partnering discussions:
Preparation is underway for planned regulatory agency meetings early next year, where Propanc management is expected to meet with the Federal Institute for Drugs and Medical Devices in Germany (BfArM), European Medicines Agency (EMA) and US Food and Drug Administration (FDA). The scientific advice meetings will be an opportunity to discuss key activities planned for the future development of PRP, including animal safety/ toxicology studies and the proposed clinical pathway for human studies in Phase I and II.
CBIS--has a potential to bring drug in the market for Phase I trial-so this will be huge.
MDBX will help them in dispensing
Levered Free Cash Flow (ttm): 6.55M , 105 Held by insiders, way undervalue , let 2016 comes this will tarde back to $55 election time more states also they are going to hook up in making the drug for phase I trials for CBIS